Table 2.

Association of 12 prostate cancer susceptibility SNPs with risk of metastatic prostate cancer, Consortium on genetic risk of metastatic and recurrent prostate cancer

SNPGeneAllelesIndia (Cornell U)Wash UPLCOSummarySummary
RR (95% CI)*RR (95% CI)*RR (95% CI)*RR (95% CI)RR (95% CI)
(212 cases and 1,442 controls) Caucasians only(470 cases and 1,945 controls) All study participants
rs10486567JAZF1C/T0.59 (0.41–0.85)0.74 (0.57–0.97)1.21 (0.77–1.89)0.98 (0.69–1.41)0.79 (0.55–1.12)
rs1089644911q13G/A0.70 (0.52–0.94)0.82 (0.65–1.04)1.16 (0.80–1.71)0.95 (0.65–1.37)0.85 (0.66–1.10)
rs10993994MSMBC/T1.41 (1.02–1.95)1.21 (0.96–1.53)1.12 (0.75–1.66)1.18 (0.96–1.51)1.24 (1.05–1.48)
rs1277172810q23T/C1.15 (0.83–1.59)1.07 (0.83–1.38)1.21 (0.82–1.79)1.10 (0.86–1.41)1.12 (0.94–1.34)
rs4072111IL16C/T0.97 (0.71–1.33)0.90 (0.59–1.37)0.88 (0.46–1.70)0.88 (0.59–1.32)0.94 (0.74–1.18)
rs42423828q24G/A1.38 (0.95–2.02)1.47 (1.08–1.98)1.24 (0.68–2.26)1.31 (0.98–1.91)1.40 (1.13–1.75)
rs4430796HNF1BT/C1.05 (0.77–1.43)0.80 (0.64–1.00)1.02 (0.68–1.52)0.92 (0.71–1.18)0.91 (0.76–1.09)
rs4782726CDH13G/A0.57 (0.37–0.89)1.04 (0.78–1.38)0.90 (0.53–1.51)0.93 (0.67–1.30)0.83 (0.57–1.21)
rs4961199CPNE3G/A1.50 (0.48–4.72)1.10 (0.77–1.55)0.49 (0.24–1.00)0.81 (0.33–1.96)0.90 (0.50–1.63)
rs4962416CTBP2A/G1.26 (0.91–1.73)1.01 (0.78–1.31)1.05 (0.81–1.31)1.02 (0.78–1.32)1.10 (0.89–1.36)
rs69820808p21G/T1.03 (0.75–1.42)1.04 (0.82–1.34)0.79 (0.51–1.23)0.93 (0.72–1.20)0.99 (0.83–1.18)
rs69832678q24G/T0.88 (0.65–1.19)0.59 (0.45–0.77)0.55 (0.37–0.83)0.55 (0.43–0.71)0.67 (0.50–0.89)

NOTE: All I2 statistics were < 20%, indicating no strong evidence of heterogeneity among studies.

  • *RR per risk allele assuming a log-additive model, adjusted for age, and race (Wash U only).

  • †The summary RRs and 95% CIs were calculated using a random-effects model, based on Caucasians only.

  • †The summary RRs and 95% CIs were calculated using a random-effects model, based on all study populations.